Cost Analysis in Helicobacter pylori Eradication Therapy Based on a Database of Health Insurance Claims in Japan
Kengo Tokunaga 1Chihiro Suzuki 2Miyuki Hasegawa 2Ikuo Fujimori 21Department of General Medicine, Kyorin University School of Medicine, Tokyo, Japan; 2Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan Correspondence: Kengo Tokunag...
Main Authors: | Tokunaga K, Suzuki C, Hasegawa M, Fujimori I |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-04-01
|
Series: | ClinicoEconomics and Outcomes Research |
Subjects: | |
Online Access: | https://www.dovepress.com/cost-analysis-in-helicobacter-pylori-eradication-therapy-based-on-a-da-peer-reviewed-article-CEOR |
Similar Items
-
Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
by: Mitsushige Sugimoto, et al.
Published: (2019-01-01) -
APPROBATION OF OPTIMIZED REGIMENS OF ERADICATION THERAPY PEPTIC ULCER OF THE STOMACH AND DUODENUM, ASSOCIATED WITH HELICOBACTER PYLORI
by: Amiraslanova I. T.
Published: (2019-11-01) -
Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens for Helicobacter Pylori Infection Eradication
by: Fariborz Mansour-Ghanaei, et al.
Published: (2017-04-01) -
Clarithromycin versus levofloxacin-based regimens for Helicobacter pylori eradication in the Kurdistan Region of Iraq: A randomized clinical trial
by: Shinah A. Mohammed, et al.
Published: (2019-09-01) -
Helicobacter pylori eradication: Current aspects
by: V V Tsukanov, et al.
Published: (2013-02-01)